{
    "id": "10:03:25_17.51.22",
    "docs_paths": null,
    "model_name": "gpt-4o-mini",
    "max_tokens": 1500,
    "temperature": 0,
    "messages": [
        {
            "role": "system",
            "content": "You are a helpful assistant!",
            "timestamp": "2025-03-10T17:51:22.104010"
        },
        {
            "role": "user",
            "content": "\nExtract a list of all organizations, companies, institutions, and other entities mentioned in this article. You must exclude all real people from your output, it should only list organizations, companies, institutions, excluding people.\n\nRequirements:\n1. Include all types of organizations (companies, government agencies, NGOs, etc.)\n2. Only include entities that are actually discussed, not just mentioned in passing\n3. Remove any duplicates\n4. Include full official names where possible.\n5. Do not include broad terms like \"government\" or \"companies\" without specific identifiers or a specific organisation.\n6. DO NOT include people.\n7. Limit the Organisation name (**ENTITY**) to a maximum of 3 to 4 words.\n8. The entity name MUST NOT be empty - if you can't identify the name, skip that entity entirely.\n\nArticle:\nTitle: Australian shares rally on renewed hopes for Fed cuts\nContent: Page 1 of 2\nFED:Australian shares rally on renewed hopes for Fed cuts\nFED:Australian shares rally on renewed hopes for Fed cuts\nAAP Newsfeed\nJanuary 16, 2025 Thursday 5:25 PM AEST\nCopyright 2025 Australian Associated Press Pty. Ltd.\nSection: FINANCIAL NEWS\nLength: 509 words\nDateline: SYDNEY Jan 16\nBody\n  The local share market has rallied after US government data showed inflation cooled more than expected in \nDecember, raising hopes the Federal Reserve would continue cutting interest rates in 2025.\n   The benchmark S&P/ASX200 index on Thursday gained 113.7 points, or 1.38 per cent, to 8,327.0, while the \nbroader All Ordinaries had climbed 112.3 points, or 1.33 per cent, to 8,569.1.\n   The gains came after US core inflation cooled to 3.2 per cent in the year from December, after remaining at 3.3 \nper cent for three months in a row.\n   GSFM investment specialist Stephen Miller said while the readout wasn't good enough to bring a January rate cut \nback into favour, it was good enough to erase any thought the Fed might not ease in 2025, a notion that had airplay \nin recent days.\n   Closer to home, a strong domestic jobs report was seen as reducing odds the Reserve Bank would cut Australian \ninterest rates in February.\n   Employment picked up by 56,300 in December, the Australian Bureau of Statistics reported on Thursday and, \nwhile unemployment ticked it up, it was still low at 4.0 per cent.\n   \"Today's release reinforces our long-running position that the RBA is unlikely to make the first rate cut until later in \nthe year,\" VanEck portfolio manager Cameron McCormack said.\n   Ultimately every sector of the ASX ground, with financials the biggest gainer, rising 2.6 per cent after US banking \ngiants JPMorgan, Citigroup, Wells Fargo and Goldman Sachs all delivered strong fourth-quarter earnings reports \novernight.\n   CBA jumped 3.0 per cent to $155.75, Westpac rose 2.5 per cent to $32.66, NAB climbed 2.8 per cent to $38.45, \nANZ advanced 2.7 per cent to $29.98 and Macquarie gained 3.2 per cent to $231.34\n   Zip soared 10 per cent to $3.09 and Afterpay owner Block rose 3.4 per cent to $138.38.\n   In the heavyweight mining sector, goldminers were up as the precious metal neared a five-week high of $US2,700 \nan ounce.\nPage 2 of 2\nFED:Australian shares rally on renewed hopes for Fed cuts\n   Evolution was up 2.8 per cent, Newmont rose 3.0 per cent and Ramelius Resources climbed 5.0 per cent.\n   BHP rose 0.5 per cent to $39.98, Fortescue added 0.3 per cent to $18.89 and Rio Tinto edged 0.1 per cent higher \nat $119.61 after releasing four-quarter production results.\n   In health care, Neuren jumped 11.5 per cent to $12.28 after the Melbourne-based biotech's drug partner, Acadia \nPharmaceuticals, asked European regulators to approve Neuren's treatment for the rare genetic disorder known as \nRett syndrome.\n   The Australian dollar was near a one-week high against the greenback, buying 62.02 US cents, from 61.88 US \ncents at close of business Wednesday.\n   ON THE ASX:\n   * The benchmark S&P/ASX200 index on Thursday gained 113.7 points, or 1.38 per cent, to 8,327.0\n   * The broader All Ordinaries rose 112.3 points, or 1.33 per cent, at 8,569.1.\n   CURRENCY SNAPSHOT:\n   One Australian dollar buys:\n   * 62.02 US cents, from 61.88 at close of business Wednesday\n   * 96.83 Japanese yen, from 97.35 yen\n   * 60.31 euro cents, from 61.88 euro cents\n   * 50.79 British pence, from 50.72 pence\n   * 110.72 NZ cents, from 110.50 NZ cents\nLoad-Date: January 16, 2025\nEnd of Document\n\nOutput Format:\n**ENTITY**: [Organization Name]\n**TYPE**: [Type of organization - e.g., Company, Government Agency, NGO, etc.]\n**DESCRIPTION**: [Brief description of how the entity is discussed in the article]\n\nExample Output:\n**ENTITY**: Tesla, Inc.\n**TYPE**: Company\n**DESCRIPTION**: Main subject of article, discussing Q4 earnings report\n\nOnly include entities that are meaningful to the article's content. Return \"None\" in case there are no relevant organisations to be mentioned.\nYou must exclude Ramelius Resources from your output.\n",
            "timestamp": "2025-03-10T17:51:22.104063"
        },
        {
            "role": "assistant",
            "content": "**ENTITY**: Federal Reserve  \n**TYPE**: Government Agency  \n**DESCRIPTION**: Discussed in relation to interest rate cuts and inflation data.\n\n**ENTITY**: Australian Bureau of Statistics  \n**TYPE**: Government Agency  \n**DESCRIPTION**: Reported on employment figures and unemployment rates in Australia.\n\n**ENTITY**: Reserve Bank of Australia  \n**TYPE**: Government Agency  \n**DESCRIPTION**: Mentioned in the context of potential interest rate cuts in Australia.\n\n**ENTITY**: JPMorgan  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned as one of the US banking giants delivering strong earnings reports.\n\n**ENTITY**: Citigroup  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned as one of the US banking giants delivering strong earnings reports.\n\n**ENTITY**: Wells Fargo  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned as one of the US banking giants delivering strong earnings reports.\n\n**ENTITY**: Goldman Sachs  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned as one of the US banking giants delivering strong earnings reports.\n\n**ENTITY**: CBA (Commonwealth Bank of Australia)  \n**TYPE**: Company  \n**DESCRIPTION**: Discussed in the context of its stock performance.\n\n**ENTITY**: Westpac  \n**TYPE**: Company  \n**DESCRIPTION**: Discussed in the context of its stock performance.\n\n**ENTITY**: NAB (National Australia Bank)  \n**TYPE**: Company  \n**DESCRIPTION**: Discussed in the context of its stock performance.\n\n**ENTITY**: ANZ (Australia and New Zealand Banking Group)  \n**TYPE**: Company  \n**DESCRIPTION**: Discussed in the context of its stock performance.\n\n**ENTITY**: Macquarie  \n**TYPE**: Company  \n**DESCRIPTION**: Discussed in the context of its stock performance.\n\n**ENTITY**: Zip  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in relation to its stock performance.\n\n**ENTITY**: Block (Afterpay)  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in relation to its stock performance and ownership of Afterpay.\n\n**ENTITY**: Evolution Mining  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in the context of its stock performance in the mining sector.\n\n**ENTITY**: Newmont  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in the context of its stock performance in the mining sector.\n\n**ENTITY**: BHP  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in the context of its stock performance in the mining sector.\n\n**ENTITY**: Fortescue Metals Group  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in the context of its stock performance in the mining sector.\n\n**ENTITY**: Rio Tinto  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned in the context of its stock performance in the mining sector.\n\n**ENTITY**: Neuren Pharmaceuticals  \n**TYPE**: Company  \n**DESCRIPTION**: Discussed in relation to its drug partner and stock performance.\n\n**ENTITY**: Acadia Pharmaceuticals  \n**TYPE**: Company  \n**DESCRIPTION**: Mentioned as Neuren's drug partner seeking regulatory approval.",
            "timestamp": "2025-03-10T17:51:29.403178"
        }
    ]
}